Technology evaluation: gene therapy (mesothelioma), NCI.
The National Cancer Institute is sponsoring a phase I clinical trial by the University of Pennsylvania involving administration of recombinant adenovirus containing the HSV-tk gene and subsequent tumor kill by ganciclovir, for the gene therapy of malignant mesothelioma. Twenty one patients have been enrolled into the trial.